CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd

Camlin Fine Sciences Acquires Majority Stake in Vinpai

November 27, 2025

Food & Beverage

Camlin Fine Sciences Limited (CFSL) completed a block acquisition of a majority stake in Vinpai, buying 78.68% of the share capital (rising to 83.82% after conversion of convertible bonds) at EUR 3.60 per share. CFSL plans a simplified cash tender offer for remaining shares and may seek a squeeze-out to delist Vinpai from Euronext Growth Paris.

Sobi Acquires CTI BioPharma Corp.

June 26, 2023

Biotechnology

Swedish Orphan Biovitrum AB (Sobi) completed the acquisition of CTI BioPharma Corp. through a cash tender offer and subsequent merger, paying USD 9.10 per share for a transaction valued at up to USD 1.7 billion. CTI, a Seattle-based biopharmaceutical company with the FDA-approved product VONJO and ~144 employees, becomes an indirect wholly owned subsidiary of Sobi and will be delisted from NASDAQ.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.

Mason Capital Acquires Forward Pharma A/S via Tender Offer

August 8, 2024

Pharmaceuticals

Mason Capital Management LLC announced the expiration and settlement of its tender offer for Forward Pharma A/S, purchasing 1,344 ADSs at $437.00 per ADS (or 0.76 DKK per ordinary share). The accepted ADSs were settled on August 1, 2024, following the July 31, 2024 expiration of the offer.

Novo Nordisk Acquires Forma Therapeutics for $1.1 billion

September 1, 2022

Biotechnology

Novo Nordisk agreed to acquire clinical-stage biopharmaceutical company Forma Therapeutics for $20 per share in cash, valuing the deal at approximately $1.1 billion. The purchase adds Forma's lead candidate etavopivat and strengthens Novo Nordisk's pipeline in sickle cell disease and other rare blood disorders; the transaction is being effected via a tender offer and is expected to close in Q4 2022, subject to customary conditions and regulatory approvals.

MediPharm Labs Corp. Acquires VIVO Cannabis Inc.

April 1, 2023

Pharmaceuticals

Effective April 1, 2023, MediPharm Labs Corp. completed an all-equity arrangement to acquire all outstanding shares of VIVO Cannabis Inc., making VIVO a wholly-owned subsidiary. Under the arrangement, former VIVO shareholders received 0.2910 MediPharm common shares per VIVO share and MediPharm issued approximately 107,930,964 shares as consideration; VIVO shares are expected to be delisted from the Toronto Stock Exchange.